(S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide tetrahydrate

Catalog No. :
ACUMDC714
CAS No. :
201677-75-0
Molecular Formula :
C17H31N7O9
Molecular Weight :
477.48

IUPAC Name:(S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide tetrahydrate

(S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide tetrahydrate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide tetrahydrate
IUPAC Name(S)-N-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide tetrahydrate
Molecular FormulaC17H31N7O9
Molecular Weight477.48
SMILESCN1C(=O)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)N2CCC[C@H]2C(N)=O)NC1=O.O.O.O.O
InChI KeyHRCJDWMUKPHPHR-NTFWNTCYSA-N
CAS No.201677-75-0

Synthetic Route by SureRoute

1. ACUMDC714 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMWJB068 route compound structure diagram
    ACMWJB068103365-69-1 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUMDC714 route product structure diagram
    ACUMDC714201677-75-0
Inquiry

2. ACUMDC714 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACHWIM476 route compound structure diagram
    ACHWIM4767531-52-4 In Stock
  4. Then
  5. ACUMDC714 route product structure diagram
    ACUMDC714201677-75-0
Inquiry

Comments (0)